According to the Press Information Bureau, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines at 30 percent of the maximum retail price (MRP) on October 17, 2026. The revised prices take effect on November 9, 2026.
The Ministry of Chemicals and Fertilizers stated that the intervention targets excessive markups along the pharmaceutical supply chain in retail and hospital pharmacies. By November 4, 2026, 70 companies reported revised MRPs for 120 drugs, showing average reductions between 20 percent and 70 percent, with the highest reduction reaching 96.45 percent.
Consumers can verify the updated prices on the NPPA website and through the Pharma Sahi Daam mobile application. The government noted that medicines already priced lower than the new limit cannot be made more expensive.
What it means
- Trade margins on 137 anti-cancer medicines are capped at 30 percent of the maximum retail price.
- The revised prices take effect on November 9, 2026.
- Medicines that are already cheaper than the new price limit cannot be made more expensive.
Source
Press Information Bureau, Government of India, “Cheaper Cancer Medicines: What the New Margin Cap Means for Patients”. Read the original release.
Summary of an official release for general information only. Not investment advice. Read the original source before acting on any information.
Official RBI, SEBI, Government and Defence updates as they happen.
Leave a Reply